Thermo Fisher Scientific (TMO) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving Thermo Fisher Scientific (TMO) right now is Bioprocessing and Biologic Drug Manufacturing Tailwind: The global shift toward biologic drugs, cell and gene therapies, and mRNA-based medicines requires single-use systems, cell culture media, filtration hardware, and purification resins that Thermo Fisher supplies at scale. Revenue (Full Year 2025) is ~$44.6 billion. If that keeps playing out, the setup is favourable; the risk to it is the most significant near-term risk is a contraction in research funding from government agencies (including NIH) and from biotech companies whose access to capital markets has historically been cyclical; when funding tightens, customers delay instrument purchases and reduce consumable orders, pressuring organic revenue growth. No one can predict where TMO trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Thermo Fisher Scientific (TMO) higher?
Bioprocessing and Biologic Drug Manufacturing Tailwind
The global shift toward biologic drugs, cell and gene therapies, and mRNA-based medicines requires single-use systems, cell culture media, filtration hardware, and purification resins that Thermo Fisher supplies at scale. Bioproduction achieved high single-digit growth in 2025, and management is expanding capacity and consumables attach rates. A multi-year build-out of biomanufacturing infrastructure across North America, Europe, and Asia represents a durable demand driver.
Recurring Consumables and Reagents Engine
Unlike pure instrument companies exposed to lumpy capital spending cycles, Thermo Fisher generates a majority of revenue from consumables, reagents, and services that customers repurchase on a regular basis. This model supports more predictable revenue and has helped the company sustain an adjusted operating margin near 22 to 23 percent even in periods of soft instrument demand. The sticky nature of proprietary reagents and single-use components creates durable pricing power.
Contract Research and Manufacturing Scale (CDMO)
The PPD clinical research organization and Patheon contract drug manufacturing platform give TMO an integrated proposition that few competitors can match: a pharmaceutical customer can design, test, manufacture, and distribute a drug largely within the Thermo Fisher ecosystem. These businesses carry multi-year backlogs and long-term contracts, providing revenue visibility and high switching costs. Clinical research delivered mid-single-digit growth in 2025.
Instrument Innovation and AI-Driven Analytical Tools
Thermo Fisher has launched a series of high-impact instruments including the Orbitrap Astral Zoom mass spectrometer and the Krios 5 Cryo-TEM, and recently unveiled AI-driven mass spectrometry platforms targeting higher-value analytical workflows. New product cycles create upgrade demand among existing customers and open new applications in proteomics, structural biology, and environmental testing. R&D investment and a broad patent estate help defend premium pricing.
What could weigh on TMO?
The most significant near-term risk is a contraction in research funding from government agencies (including NIH) and from biotech companies whose access to capital markets has historically been cyclical; when funding tightens, customers delay instrument purchases and reduce consumable orders, pressuring organic revenue growth. Thermo Fisher's active acquisition strategy carries integration and leverage risk, particularly after committing approximately $13 billion to mergers and acquisitions in 2025 alone, and a large deal that underperforms expectations could weigh on earnings and the balance sheet simultaneously. Geopolitical friction, particularly regarding China, creates both a demand risk (softer orders from Chinese academic and industrial customers) and a supply chain risk, while tariff policy changes can disrupt cost structures. Finally, the stock's valuation, though below its own ten-year average on a trailing price-to-earnings basis, still prices in sustained mid-single-digit organic growth, leaving limited room for disappointment if end markets soften.
How to think about a TMO forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the TMO guide and whether TMO is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the TMO outlook
The bottom line: what is driving Thermo Fisher Scientific (TMO) is Bioprocessing and Biologic Drug Manufacturing Tailwind, with revenue (full year 2025) at ~$44.6 billion. If that keeps playing out the setup is favourable; the risk is the most significant near-term risk is a contraction in research funding from government agencies (including NIH) and from biotech companies whose access to capital markets has historically been cyclical; when funding tightens, customers delay instrument purchases and reduce consumable orders, pressuring organic revenue growth. No one can predict the price, so treat any TMO forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around TMO with Walnut
Use Thermo Fisher Scientific as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Thermo Fisher Scientific (TMO)?
+
No one can reliably predict where TMO will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Thermo Fisher Scientific higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive TMO higher?
+
The main growth drivers are Bioprocessing and Biologic Drug Manufacturing Tailwind; Recurring Consumables and Reagents Engine; Contract Research and Manufacturing Scale (CDMO). Whether they play out is the real question, not a guaranteed path.
What are the risks to TMO?
+
The most significant near-term risk is a contraction in research funding from government agencies (including NIH) and from biotech companies whose access to capital markets has historically been cyclical; when funding tightens, customers delay instrument purchases and reduce consumable orders, pressuring organic revenue growth. Thermo Fisher's active acquisition strategy carries integration and leverage risk, particularly after committing approximately $13 billion to mergers and acquisitions in 2025 alone, and a large deal that underperforms expectations could weigh on earnings and the balance sheet simultaneously. Geopolitical friction, particularly regarding China, creates both a demand risk (softer orders from Chinese academic and industrial customers) and a supply chain risk, while tariff policy changes can disrupt cost structures. Finally, the stock's valuation, though below its own ten-year average on a trailing price-to-earnings basis, still prices in sustained mid-single-digit organic growth, leaving limited room for disappointment if end markets soften.
Will TMO stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Thermo Fisher Scientific's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is TMO a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the TMO "is it a buy?" page for a framework. Walnut is not an investment adviser.
What is Thermo Fisher's growth outlook for 2026?
+
Management guided for full-year 2026 revenue of approximately $46.3 to $47.2 billion, representing 4 to 6 percent growth, and adjusted EPS of $24.22 to $24.80, representing 6 to 8 percent growth versus 2025. Key drivers cited are bioproduction recovery, clinical research services, and new instrument cycles. Organic revenue growth remains the variable most closely watched by investors given the post-pandemic normalization period.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.